Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
B7H6 belongs to the B7 family (see MIM 605402) and is selectively expressed on tumor cells. De plus, nous expédions Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1 Protéines (17) et Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1 Kits (5) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 80 products:
Human Monoclonal NCR3LG1 Primary Antibody pour CyTOF, FACS - ABIN4899034
Fielding, Weekes, Nobre, Ruckova, Wilkie, Paulo, Chang, Suárez, Davies, Antrobus, Stanton, Aicheler, Nichols, Vojtesek, Trowsdale, Davison, Gygi, Tomasec, Lehner, Wilkinson: Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation. dans eLife 2017
Show all 2 Pubmed References
B7-H6 was expressed in gliomas and correlated with glioma progression. Knockdown of B7-H6 inhibited glioma cell proliferation, colony formation, migration, and invasion via upregulation of E-cadherin and Bax, and downregulation of vimentin, N-cadherin, MMP-2, MMP-9 and survivin.
these studies find that soluble B7H6 is constitutively expressed during pregnancy
Data suggest that B7-H6 play an important role in the regulation of the biological behavior of glioma cells.
Data indicate a sequence of events driven by tumour-derived prostaglandin D2 (PGD2 (Montrer PTGDS Anticorps)) associated with engagement of the natural cytotoxicity triggering receptor 3 (NKp30 (Montrer NCR3 Anticorps))-B7H6 antigen (B7H6) pathway leading to significant group 2 innate lymphoid cells (ILC2s) activation and expansion.
B7H6-derived peptides trigger TNF-alpha (Montrer TNF Anticorps)-dependent immunostimulatory activity of lymphocytic NK92-MI cells.
Study confirms that B7-H6 is widely expressed in B-cell lymphomas and demonstrates its important role in the pathogenesis and chemosensitivity of lymphoma.
our present data revealed that higher B7-H6 expression in ovarian cancer tissues was positively correlated with tumor metastasis and cancer progression
NKp30 (Montrer NCR3 Anticorps)-B7-H6 interaction is a novel cell contact mechanism that mediates activation of Group 2 innate lymphoid cells and identifies a potential target for the development of novel therapeutics for atopic dermatitis and other atopic diseases.
study not only reveals the possibility that tumor therapeutics work as stress inducers to enhance tumor sensitivity to NK cell cytolysis but also suggests that B7-H6 could be a potential target for tumor therapy in the future
Our results suggest that NKP30 (Montrer NCR3 Anticorps)-B7-H6 interaction can aggravate hepatocyte damage, probably through up-regulation of IL-32 (Montrer IL32 Anticorps) expression in hepatitis B virus-related acute-on-chronic liver failure
B7H6 belongs to the B7 family (see MIM 605402) and is selectively expressed on tumor cells. Interaction of B7H6 with NKp30 (NCR3\; MIM 611550) results in natural killer (NK) cell activation and cytotoxicity (Brandt et al., 2009
B7 homolog 6
, natural cytotoxicity triggering receptor 3 ligand 1
, putative Ig-like domain-containing protein DKFZp686O24166/DKFZp686I21167